Index RUT P/E - EPS (ttm) -0.42 Insider Own 8.42% Shs Outstand 138.13M Perf Week 1.74%
Market Cap 436.57M Forward P/E - EPS next Y -0.23 Insider Trans 0.11% Shs Float 136.46M Perf Month 3.17%
Income -59.56M PEG - EPS next Q -0.09 Inst Own 38.18% Short Float 7.85% Perf Quarter 38.86%
Sales 181.41M P/S 2.41 EPS this Y 14.81% Inst Trans -3.01% Short Ratio 7.03 Perf Half Y 37.56%
Book/sh -0.13 P/B - EPS next Y 38.70% ROA -18.04% Short Interest 10.71M Perf Year 54.21%
Cash/sh 0.52 P/C 5.63 EPS next 5Y - ROE -617.16% 52W Range 1.46 - 3.26 Perf YTD 24.68%
Dividend Est. - P/FCF - EPS past 5Y 38.13% ROI -24.29% 52W High -10.12% Beta 1.85
Dividend TTM - Quick Ratio 1.69 Sales past 5Y 195.35% Gross Margin 77.74% 52W Low 100.68% ATR (14) 0.15
Dividend Ex-Date - Current Ratio 2.26 EPS Y/Y TTM 19.39% Oper. Margin -20.50% RSI (14) 62.91 Volatility 4.46% 5.47%
Employees 377 Debt/Eq - Sales Y/Y TTM 35.31% Profit Margin -32.83% Recom 1.00 Target Price 4.67
Option/Short Yes / Yes LT Debt/Eq - EPS Q/Q 29.97% Payout - Rel Volume 1.27 Prev Close 2.96
Sales Surprise 1.46% EPS Surprise -3.09% Sales Q/Q 26.46% Earnings Aug 08 BMO Avg Volume 1.52M Price 2.93
SMA20 5.11% SMA50 13.02% SMA200 25.07% Trades
Volume 1,939,413 Change -1.01%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated Oppenheimer
Outperform
$5
Aug-28-23 Initiated Craig Hallum
Buy
$4.50
Oct-21-22 Initiated Jefferies
Buy
$4
Apr-28-22 Initiated Craig Hallum
Buy
$6.50
Nov-17-21 Initiated SVB Leerink
Outperform
$6
Oct-29-21 Initiated H.C. Wainwright
Buy
$4
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$11
Feb-18-20 Initiated Piper Sandler
Overweight
$12
Jul-16-18 Initiated RBC Capital Mkts
Outperform
$24
Jul-16-18 Initiated Leerink Partners
Outperform
$24
Jul-16-18 Initiated Jefferies
Buy
$23
Show Previous Ratings
Aug-22-24 07:00AM
Aug-08-24 08:25AM
07:30AM
(Associated Press Finance)
07:00AM
Aug-01-24 10:01AM
07:00AM
Loading…
Jul-25-24 07:00AM
Jul-24-24 09:55AM
Jul-08-24 07:00AM
Jul-03-24 01:05PM
Jun-03-24 07:00AM
May-30-24 07:30AM
07:00AM
May-10-24 03:21PM
12:36PM
12:27AM
(Thomson Reuters StreetEvents)
11:55AM
Loading…
May-09-24 11:55AM
08:10AM
07:11AM
(Associated Press Finance)
07:00AM
May-06-24 07:42AM
07:00AM
May-02-24 07:00AM
Apr-03-24 04:05PM
Apr-02-24 07:00AM
Mar-07-24 01:47PM
11:56AM
Mar-06-24 11:16PM
(Thomson Reuters StreetEvents) -19.48%
12:52PM
08:15AM
07:17AM
(Associated Press Finance)
07:02AM
Loading…
07:02AM
07:00AM
Mar-05-24 09:42AM
Feb-28-24 07:00AM
Feb-05-24 07:00AM
Jan-11-24 08:30AM
Jan-10-24 08:00AM
Jan-08-24 02:48PM
Jan-05-24 04:05PM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-23-23 07:32PM
Dec-20-23 02:00PM
Nov-17-23 01:07PM
Nov-10-23 04:00PM
01:53AM
(Thomson Reuters StreetEvents)
Nov-09-23 11:30AM
08:10AM
07:17AM
(Associated Press Finance)
07:00AM
Oct-26-23 06:15PM
Oct-16-23 07:00AM
Sep-27-23 08:00AM
Sep-20-23 07:36AM
Sep-14-23 04:05PM
Aug-28-23 07:00AM
Aug-17-23 11:00AM
Aug-11-23 09:09AM
Aug-10-23 11:59AM
Aug-08-23 12:05PM
09:15AM
07:13AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jun-29-23 04:19PM
(News Direct) -10.98%
+11.49%
Jun-22-23 01:50PM
Jun-21-23 07:00AM
Jun-19-23 12:58PM
Jun-01-23 07:00AM
May-09-23 11:33PM
(Thomson Reuters StreetEvents) +13.75%
+7.33%
07:25AM
07:00AM
May-08-23 06:37AM
May-02-23 07:00AM
Apr-18-23 07:00AM
Apr-17-23 06:25AM
Apr-06-23 08:21AM
Apr-05-23 01:18PM
Mar-30-23 07:00AM
Mar-29-23 04:05PM
Mar-08-23 11:52PM
(Thomson Reuters StreetEvents) -11.76%
-7.41%
06:00AM
Feb-23-23 07:00AM
Feb-02-23 07:00AM
Jan-30-23 07:00AM
Jan-05-23 04:03PM
07:00AM
Dec-31-22 09:33AM
Dec-15-22 07:00AM
Nov-24-22 10:56AM
Nov-23-22 06:00AM
Nov-16-22 09:53AM
Nov-09-22 07:00AM
Nov-02-22 10:01AM
07:00AM
Nov-01-22 07:00AM
Oct-20-22 10:28AM
06:00AM
Oct-06-22 06:07AM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schmid John P. Director Aug 12 '24 Buy 2.25 4,515 10,147 25,200 Aug 13 04:15 PM Schmid John P. Director Aug 09 '24 Buy 2.37 4,285 10,134 20,685 Aug 12 06:28 PM Schmid John P. Director May 10 '24 Buy 1.91 5,400 10,314 16,400 May 10 04:04 PM JOHNSON JOHN Director Mar 18 '24 Option Exercise 1.99 215,600 429,044 751,412 Mar 18 05:32 PM Schmid John P. Director Mar 14 '24 Buy 2.16 4,500 9,720 11,000 Mar 14 09:03 PM SHERMAN JEFFREY W Director Nov 27 '23 Buy 1.87 5,400 10,098 5,400 Nov 29 04:09 PM HALKUFF DAWN Director Nov 20 '23 Buy 1.84 5,410 9,954 5,410 Nov 21 04:20 PM Pieper Steven See Remarks Nov 20 '23 Buy 1.95 28,000 54,600 1,176,912 Nov 21 04:16 PM Schmid John P. Director Nov 16 '23 Buy 1.51 6,500 9,815 6,500 Nov 17 06:35 PM Shannon John Patrick Jr See Remarks Nov 17 '23 Buy 1.64 30,769 50,400 1,408,575 Nov 17 05:58 PM PERSKY MARLA Director Nov 14 '23 Buy 1.58 6,370 10,058 6,370 Nov 15 04:13 PM
Index RUT P/E - EPS (ttm) -0.90 Insider Own 43.30% Shs Outstand 56.47M Perf Week 6.14%
Market Cap 332.93M Forward P/E - EPS next Y -1.17 Insider Trans -3.11% Shs Float 32.10M Perf Month 12.00%
Income -50.53M PEG - EPS next Q -0.24 Inst Own 41.68% Short Float 6.83% Perf Quarter 73.96%
Sales 0.00M P/S - EPS this Y 23.25% Inst Trans 3.10% Short Ratio 8.34 Perf Half Y 80.37%
Book/sh 4.61 P/B 1.27 EPS next Y -28.47% ROA -17.39% Short Interest 2.19M Perf Year 139.02%
Cash/sh 4.61 P/C 1.28 EPS next 5Y - ROE -18.11% 52W Range 1.96 - 6.91 Perf YTD 121.89%
Dividend Est. - P/FCF - EPS past 5Y -138.68% ROI -19.20% 52W High -14.91% Beta 1.83
Dividend TTM - Quick Ratio 41.42 Sales past 5Y 0.00% Gross Margin - 52W Low 200.00% ATR (14) 0.47
Dividend Ex-Date - Current Ratio 41.42 EPS Y/Y TTM 32.44% Oper. Margin 0.00% RSI (14) 63.14 Volatility 6.23% 9.79%
Employees 124 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 2.33 Target Price 7.00
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 41.48% Payout - Rel Volume 2.17 Prev Close 5.86
Sales Surprise - EPS Surprise 9.99% Sales Q/Q - Earnings Aug 05 BMO Avg Volume 262.83K Price 5.88
SMA20 14.06% SMA50 22.93% SMA200 63.39% Trades
Volume 570,011 Change 0.34%
Date
Action
Analyst
Rating Change
Price Target Change
May-07-24 Upgrade Piper Sandler
Neutral → Overweight
$6 → $12
Nov-14-23 Downgrade Piper Sandler
Overweight → Neutral
$42 → $6
Aug-15-23 Downgrade Wedbush
Outperform → Neutral
$19 → $6
Aug-15-23 Downgrade SVB Securities
Outperform → Market Perform
$6
Aug-15-23 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$23 → $7
May-04-23 Upgrade Goldman
Sell → Neutral
$6
Jun-10-22 Initiated Wedbush
Outperform
$21
May-02-22 Initiated RBC Capital Mkts
Outperform
$30
Jan-19-22 Initiated Goldman
Sell
$10
Apr-20-21 Initiated SVB Leerink
Outperform
$36
Apr-20-21 Initiated Piper Sandler
Overweight
$42
Apr-20-21 Initiated Goldman
Neutral
$28
Show Previous Ratings
Sep-10-24 08:00AM
Aug-21-24 09:55AM
Aug-05-24 08:00AM
May-22-24 08:50PM
May-10-24 03:36PM
11:55PM
Loading…
May-08-24 11:55PM
04:05PM
May-07-24 07:12AM
06:30AM
Mar-20-24 10:31AM
06:58AM
(Thomson Reuters StreetEvents)
Mar-19-24 08:53PM
05:33PM
04:01PM
Mar-12-24 06:30AM
12:00PM
Loading…
Dec-18-23 12:00PM
Nov-14-23 07:28PM
Nov-13-23 04:05PM
Aug-15-23 03:02PM
09:59AM
02:34AM
Aug-14-23 04:05PM
04:01PM
Jun-18-23 08:03AM
May-31-23 06:30AM
May-09-23 04:05PM
May-08-23 06:05AM
Apr-24-23 06:30AM
Apr-11-23 09:55AM
Apr-04-23 02:47PM
04:05PM
Loading…
Mar-14-23 04:05PM
Mar-09-23 06:33AM
Feb-08-23 06:30AM
Dec-21-22 06:46AM
Dec-14-22 05:15AM
Dec-07-22 04:01PM
(GlobeNewswire) -6.00%
-33.33%
Nov-28-22 10:37AM
Nov-03-22 04:05PM
Oct-17-22 04:05PM
Sep-22-22 06:30AM
Aug-08-22 04:05PM
Aug-03-22 06:30AM
Jun-21-22 09:57AM
Jun-01-22 06:30AM
May-09-22 04:05PM
Mar-30-22 06:30AM
Mar-23-22 02:53PM
Mar-10-22 04:02PM
Mar-09-22 06:30AM
Feb-28-22 04:05PM
Feb-10-22 06:30AM
Feb-01-22 04:05PM
Jan-19-22 12:51PM
Dec-23-21 05:00AM
Nov-09-21 04:05PM
Sep-24-21 07:55AM
Sep-08-21 06:30AM
Sep-03-21 07:33AM
Aug-09-21 04:05PM
Jun-26-21 04:30AM
Jun-07-21 04:10PM
04:05PM
May-10-21 04:05PM
Mar-30-21 04:05PM
Mar-25-21 11:56PM
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
William Arsani Director Aug 09 '24 Sale 4.25 814,874 3,463,214 0 Aug 12 04:30 PM Logos SPV 1 LP Director Aug 09 '24 Proposed Sale 4.24 814,874 3,455,066 Aug 09 04:20 PM Schmid John P. Director Mar 25 '24 Buy 3.74 17,809 66,606 26,965 Mar 25 07:10 PM Schmid John P. Director Mar 22 '24 Buy 3.62 9,156 33,133 9,156 Mar 25 07:10 PM Berger Heather A. Director Mar 25 '24 Buy 3.74 1,300 4,866 1,300 Mar 25 07:09 PM LAPPE RODNEY W Director Sep 29 '23 Buy 2.35 21,000 49,287 133,024 Oct 02 06:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
